title: Nardostachys jatamansi extract protects against cytokine-induced beta-cell damage and streptozotocin-induced diabetes.
abstract: OBJECTIVE
  To investigate the anti-diabetogenic mechanism of Nardostachys jatamansi extract (NJE).
  
  
  METHODS
  Mice were injected with streptozotocin via a tail vein to induce diabetes. Rat insulinoma RINm5F cells and isolated rat islets were treated with interleukin-1beta and interferon-gamma to induce cytotoxicity.
  
  
  RESULTS
  Treatment of mice with streptozotocin resulted in hyperglycemia and hypoinsulinemia, which was confirmed by immunohistochemical staining of the islets. The diabetogenic effects of streptozotocin were completely abolished when mice were pretreated with NJE. Inhibition of streptozotocin-induced hyperglycemia by NJE was mediated by suppression of nuclear factor (NF)-kappaB activation. In addition, NJE protected against cytokine-mediated cytotoxicity. Incubation of RINm5F cells and islets with NJE resulted in a significant reduction in cytokine-induced NF-kappaB activation and downstream events, inducible nitric oxide synthase expression and nitric oxide production. The protective effect of NJE was further demonstrated by the normal insulin secretion of cytokine-treated islets in response to glucose.
  
  
  CONCLUSIONS
  NJE provided resistance to pancreatic beta-cell damage from cytokine or streptozotocin treatment. The beta-cell protective effect of NJE is mediated by suppressing NF-kappaB activation.
authors.affiliation: Department of Biochemistry, Medical School and Diabetes Research Center, Chonbuk National University, Jeonju, Jeonbuk 561-756, South Korea.
authors.forename: Mi-Young
authors.initials: MY
authors.lastname: Song
authors.forename: Ui-Jin
authors.initials: UJ
authors.lastname: Bae
authors.forename: Bong-Hee
authors.initials: BH
authors.lastname: Lee
authors.forename: Kang-Beom
authors.initials: KB
authors.lastname: Kwon
authors.forename: Eun-A
authors.initials: EA
authors.lastname: Seo
authors.forename: Sung-Joo
authors.initials: SJ
authors.lastname: Park
authors.forename: Min-Sun
authors.initials: MS
authors.lastname: Kim
authors.forename: Ho-Joon
authors.initials: HJ
authors.lastname: Song
authors.forename: Keun-Sang
authors.initials: KS
authors.lastname: Kwon
authors.forename: Jin-Woo
authors.initials: JW
authors.lastname: Park
authors.forename: Do-Gon
authors.initials: DG
authors.lastname: Ryu
authors.forename: Byung-Hyun
authors.initials: BH
authors.lastname: Park
mesh_terms: D000818:Animals; D001483:Base Sequence; D016923:Cell Death / Q000187:drug effects; D002460:Cell Line; D016207:Cytokines / Q000037:antagonists & inhibitors* / Q000633:toxicity*; D017931:DNA Primers / Q000235:genetics; D003921:Diabetes Mellitus, Experimental / Q000517:prevention & control*; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D066298:In Vitro Techniques; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D050417:Insulin-Secreting Cells / Q000187:drug effects* / Q000473:pathology / Q000502:physiology; D007371:Interferon-gamma / Q000037:antagonists & inhibitors / Q000633:toxicity; D053583:Interleukin-1beta / Q000037:antagonists & inhibitors / Q000633:toxicity; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D016328:NF-kappa B / Q000378:metabolism; D032404:Nardostachys; D052247:Nitric Oxide Synthase Type II / Q000235:genetics; D010936:Plant Extracts / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D016207:Cytokines; D017931:DNA Primers; D007004:Hypoglycemic Agents; D007328:Insulin; D053583:Interleukin-1beta; D016328:NF-kappa B; D010936:Plant Extracts; D007371:Interferon-gamma; D052247:Nitric Oxide Synthase Type II; C496318:Nos2 protein, rat